trending Market Intelligence /marketintelligence/en/news-insights/trending/3waymAdMUTDw7dWnsqSZwQ2 content esgSubNav
In This List

Revance raises $127.1M from stock offering

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Revance raises $127.1M from stock offering

Revance Therapeutics Inc. said it raised $127.1 million after underwriters of its previously announced offering fully exercised their overallotment option.

The Newark, Calif.-based biotechnology company sold 7,475,000 shares at $17 apiece, including the additional 975,000 shares as part of underwriters' overallotment option.

Cowen, Piper Jaffray & Co. and Stifel are joint lead book-running managers for the offering, with Guggenheim Securities serving as book-running manager and Needham & Co. as co-manager.

On Nov. 26, 2019, the company filed an application to the U.S. Food and Drug Administration seeking approval for Daxi, the company's competitor to Allergan PLC's botox.